Citadel Advisors’s SOPHiA GENETICS SOPH Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q2
Sell
-3,800
Closed -$12.6K 14897
2025
Q1
$12.6K Buy
3,800
+3,300
+660% +$11.6K ﹤0.01% 13434
2024
Q4
$1.56K Buy
500
+200
+67% +$681 ﹤0.01% 14174
2024
Q3
$1.09K Buy
+300
New +$1.22K ﹤0.01% 13902
2023
Q4
Sell
-100
Closed -$255 15180
2023
Q3
$255 Buy
+100
New +$317 ﹤0.01% 14110

Other funds holding SOPH

Citadel Advisors's SOPH Position: Q2 2026 in Review

Citadel Advisors opened a new position in SOPHiA GENETICS (SOPH) in Q2 2026: 38,497 shares worth $222K. The stake represents ﹤0.01% of the portfolio and ranks #11822 among its holdings. This is a return to the name: Citadel Advisors previously reported a position in SOPH as recently as Q3 2025.

Citadel Advisors first reported a position in SOPH in Q4 2021 and has held it in 13 quarters since. The position peaked at $334K in Q1 2023. 71 funds tracked by Wall St. Rank hold SOPH as of Q2 2026.

  • Citadel Advisors held 38,497 shares of SOPHiA GENETICS worth $222K as of Q2 2026.
  • SOPHiA GENETICS was a new Citadel Advisors position in Q2 2026.
  • SOPHiA GENETICS made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #11822 holding.
  • Citadel Advisors first reported a position in SOPHiA GENETICS in Q4 2021 and has held it in 13 quarters since.
  • Citadel Advisors's SOPHiA GENETICS position peaked at $334K in Q1 2023.
  • 71 funds tracked by Wall St. Rank held SOPHiA GENETICS as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.